ClinicalTrials.gg
Not yet recruitingNCT07456501FUSEUpdated Mar 6, 2026

Fluoxetine and Understanding Social Experiences

An interventional study of Fluoxetine and Placebo in Depression in Adolescence, Antidepressant Activity in Healthy Volunteers and Healthy Adult Participants, sponsored by University of Oxford. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by University of Oxford · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.

Planned enrollment
24th of 42
80 · median 97
Started
2026
with 1 other
No phase
10 of 43
3 open now
Registered
42nd of 43
by date
Lead sponsor
3 of 43
University of Oxford

Among the 43 studies testing fluoxetine in Depression, this one is the 24th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 42nd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About fluoxetine

Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing fluoxetine in Depression, or all of them as a file.
02

Study summary

Adolescence is a critical developmental period marked by significant social, cognitive, and emotional changes. Unfortunately, it is also a time when the risk of depression and anxiety rises dramatically. Early, effective treatment is essential to mitigate long-term impacts on relationships, education, and life satisfaction. While psychological therapies are recommended as first-line treatment for mild to moderate depression in young people, antidepressant use (particularly SSRIs such as Prozac) has risen sharply, especially among girls aged 15-17.

Despite their widespread use, there is limited research on how SSRIs address adolescent depression, leaving clinicians with little evidence to guide treatment decisions. The Fluoxetine and Understanding Social Experiences (FUSE) study aims to shed light on how Prozac (medically known as fluoxetine) influences decision-making in healthy young people in four key areas that are known to be affected by depression: emotional processing (e.g., facial expression recognition), social function (e.g., sensitivity to peer rejection), reward processing (e.g., how people learn from rewards and punishments), and motivation (e.g., how people make decisions about whether a certain outcome or reward is worth the effort to obtain). Some of the tests employed in the study use facial expression and heart-rate recording as aditional measures. We are aiming to recruit and test 80 young people between the ages of 18 and 24.

When included in the study, participants are randomly assigned to receive either a weeklong treatment with fluoxetine, or a placebo (a pill with no active ingredients). The study follows a double-blind design, which means that neither the researchers nor the participants are aware of the treatment received so as to not influence the results.

We belive that fluoxetine will have beneficial effects on social decision-making in young people, which might manifest as increased accuracy labelling positive facial expressions, less sensitivity to negative feedback, lower self-reported negative mood in response to social exclusion and reduced heart rate/negative facial expressivity in response to unpleasant social experiences.

The FUSE study aims to deepen our understanding of how antidepressants affect decision-making in young people, at a time when antidepressant prescriptions have risen but research is scarce. By identifying the exact domains of functioning which are affected by antidepressant use in this age group, this research will help inform which young people are likely to benefit most from drug treatment.

The project results will be published in peer-reviewed journals and presented at academic conferences. We are also working with a group of young advisors who will help us decide how to best share our results with others in their age group. A brief summary of the study findings will also be provided to participants who would like to receive it. All research data, excluding information that could identify participants, will be stored safely for at least 10 years after final publication or public release.

03

Conditions studied

  • Depression in Adolescence
  • Antidepressant Activity in Healthy Volunteers
  • Healthy Adult Participants

Browse trials for

Keywords

  • Depression
  • Adolescent depression
  • Fluoxetine
  • Prozac
  • Young people
  • Reward processing
  • Effort-based decision-making
  • Social cognition
  • Peer rejection
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged 18-24 years (inclusive)
  • Be resident in the UK for the duration of the study
  • Have normal or corrected to normal vision
  • Participant is willing and able to give for participation in the research
  • Sufficiently fluent English to understand and complete the study

Exclusion criteria

Exclusion Criteria:

Psychiatric History:

  • Current or past diagnosis of any psychiatric disorder, as determined by the SCID-5 and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;
  • First degree relative with a diagnosis of mania.

Lifestyle:

  • Heavy smoker or vaper (> 10 cigarettes per day, or >2 mL e-liquid, or >15mg/day from a nicotine patch);
  • Heavy use of caffeine (drink > 4 of 250ml cups/cans of coffee or energy drinks per day);
  • Heavy alcohol drinker (drink >14 standard alcoholic drinks per week);
  • Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances.
  • Unable or unwilling to consume gelatine (study capsules will be gelatine-based).

Physical Health:

  • Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;
  • Known to fluoxetine, such as to fluoxetine or any component in its formulation;
  • Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;
  • Breastfeeding.

Medical History:

  • Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study. This can include but is not limited to: seizures or epilepsy, abnormal heart rhythm, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);
  • Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury);
  • Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor. This can include but is not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm.

Prior Study Participation:

  • Participation in any other psychological or medical experiment involving taking any kind of drug/medication/vaccine, within the last 3 months;
  • Participation in any other study involving the current or similar tasks, within the last 6 months.

Other considerations:

•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's safety or ability to participate in the study.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fluoxetine

    Drug: Fluoxetine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will be taking a 20mg fluoxetine capsule daily for 7 days.

  • DrugPlacebo

    Participants will be taking a placebo capsule daily for 7 days.

06

What researchers measure

Primary outcomes

  1. Behavioural measure: Facial Expression Recognition Task (FERT)

    Recognition of positive (happy, surprise) faces in the Facial Expression Recognition Task.

    Time frame: On the last day of the 7-day treatment

Secondary outcomes

  1. Self-report measure: the Need Threat Scale

    Participant scores on the 20-item Need Threat Scale, administered after the Cyberball task (an ostracism paradism). The scale ssesses self-reported current satisfaction levels with belonging, self-esteem, meaningful existence, and control on 7-point scales ranging from 1 (do not agree) to 7 (agree), serving as a proxy of whether these needs are threatened.

    Time frame: On the last day of the 7-day treatment

  2. Behavioural measure: Probabilistic Reversal Learning Task

    Performance on a probabilistic reversal learning task, in which participants learn probabilistic reward contingencies associated with three stimulus images, and them must relearn when those contingencies are reversed.

    Time frame: On the last day of the 7-day treatment

  3. Behavioural measure: Piggybank Task

    Performance on a task measuring action vigour, where participants have to earn monetary rewards by pressing keys to "shake" coins from virtual piggy banks. Piggybanks vary in effort and reward, requiring ongoing adjustment.

    Time frame: On the last day of the 7-day treatment

  4. Self-report measure: Perception of social rejection on the Verbal Interaction Social Threat (VIST) Task

    In the Verbal Interaction Social Threat Task, participants are led to believe they will be engaging in an online interaction with two other study participants. Participants are shown a series of prompts and, for each one, choose one of four possible "icebreaker" sentences (for example, under the theme of sport: "I play a team sport such as football, rugby or netball" or "I play an individual sport like tennis or athletics"). After each choice, they receive responses that appear to be typed in real time by the two peers. In reality, these responses are pre-programmed and skewed toward negative feedback for most prompts (e.g., a peer might reply "I think team sports are more like a game than a real sport"). Following each exchange, participants rate how positively or negatively they perceived the interaction.

    Time frame: On the last day of the 7-day treatment

  5. Behavioural measure: Proportion of anger-related solutions found on the Word Completion Task

    In this task, participants complete word puzzles with multiple solutions, many allowing aggression-related words (e.g., k n \_ \_ \_ as "knees" or "knife"). It follows the VIST rejection paradigm, which is expected to reduce social cohesion and increase anti-social thought.

    Time frame: On the last day of the 7-day treatment

Other outcomes

  1. Physiological measure: Heart Rate Variability in response to social rejection

    Heart rate variability measures across tasks inducing social rejection.

    Time frame: On the last day of the 7-day treatment

  2. Physiological measure: Facial Expression in response to social rejection

    Video recordings that identify facial expressions across tasks inducing social rejection.

    Time frame: On the last day of the 7-day treatment

07

Study locations

1 site
  • University of Oxford Department of Psychiatry
    Oxford, OX3 7JX, United Kingdom
    • Andreea Raslescu · Contactandreea.raslescu@psych.ox.ac.uk · +44 1865 618245
    • Catherine Harmer, DPhil, MA, DipLATHE · Principal investigator
    • Susannah Murphy, DPhil · Sub investigator
    • Andreea Raslescu, DPhil · Sub investigator
08

References and documents

Publications

  • Murphy SE, Capitao LP, Giles SLC, Cowen PJ, Stringaris A, Harmer CJ. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry. 2021 Sep;8(9):824-835. doi: 10.1016/S2215-0366(21)00154-1. PubMed 34419187 ↗

Individual participant data

Plan to share: Yes — Data which has been fully de-identified and relevant supporting materials (e.g., study protocol, data dictionary, and analysis documentation) may be shared with other academic organisations in the future, including those outside of the UK and the EU. Participants will be informed of this and specific consent for this will be obtained.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available within 6 months of data collection completion (end 2027).

Access criteria: Fully de-identified individual participant data (IPD) and relevant supporting documentation may be shared with academic researchers for scientific research purposes. Access will be limited to researchers affiliated with recognised academic or research institutions, including those outside of the UK and EU. Approved researchers will be granted access only to fully de-identified IPD and relevant supporting materials. Data will be shared via secure transfer methods or through a controlled-access data repository.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jul 2027, 16 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 16 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartEst.
Mar 2026
Primary completionEst.
Jul 20, 2027
CompletionEst.
Jul 22, 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456501
Collaborators
Wellcome Trust, National Institute for Health Research, United Kingdom
Responsible party
Catherine Harmer (Professor of Cognitive Neuroscience, University of Oxford) — Principal investigator
First posted
Mar 6, 2026
Start date
Mar 2026 (estimated)
Primary completion
Jul 20, 2027 (estimated)
Completion
Jul 22, 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Catherine Harmer
Contact
catherine.harmer@psych.ox.ac.uk
+44 1865 618326
Andreea Raslescu
Contact
andreea.raslescu@psych.ox.ac.uk
+44 1865 618245

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoxetine

Start the discussion